percentage of patients with a favorable outcome in the two arms an expected average of 14 days [clinicaltrials_resource:374f8e5301925e8c6a6925039fb2b4ae]
The proportions of participants with a favourable outcome will be calculated in the meropenem arm and in the SOC arm. A favourable outcome is met when an infant:
Is alive
Has resolution or significant improvement of all abnormalities that defined LOS at entry and has no new clinical or laboratory abnormalities requiring a new course of antibiotic therapy
Has microbiological eradication either confirmed or presumed and no new pathogens identified.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
percentage of patients with a favorable outcome in the two arms an expected average of 14 days [clinicaltrials_resource:374f8e5301925e8c6a6925039fb2b4ae]
The proportions of participants with a favourable outcome will be calculated in the meropenem arm and in the SOC arm. A favourable outcome is met when an infant:
Is alive
Has resolution or significant improvement of all abnormalities that defined LOS at entry and has no new clinical or laboratory abnormalities requiring a new course of antibiotic therapy
Has microbiological eradication either confirmed or presumed and no new pathogens identified.
Bio2RDF identifier
374f8e5301925e8c6a6925039fb2b4ae
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:374f8e5301925e8c6a6925039fb2b4ae
measure [clinicaltrials_vocabulary:measure]
percentage of patients with a favorable outcome in the two arms
time frame [clinicaltrials_vocabulary:time-frame]
an expected average of 14 days
description
The proportions of participant ...... d no new pathogens identified.
identifier
clinicaltrials_resource:374f8e5301925e8c6a6925039fb2b4ae
title
percentage of patients with a ...... an expected average of 14 days
@en
type
label
percentage of patients with a ...... f8e5301925e8c6a6925039fb2b4ae]
@en